Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials-Reference-Cited by-同舟云学术

Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials

Published:2014-09-18 Issue:12 Volume:124 Page:1968-1975
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

van Es Nick¹,Coppens Michiel¹,Schulman Sam²,Middeldorp Saskia¹,Büller Harry R.¹

Affiliation:

1. Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands; and

2. Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada

Abstract

Key Points DOACs have similar efficacy as VKAs in the treatment of acute symptomatic VTE, but significantly reduce the risk of major bleeding. The efficacy and safety of DOACs in the treatment of acute VTE are consistent in clinically important subgroups.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/12/1968/1379490/1968.pdf

Reference16 articles.

1. Dabigatran versus warfarin in the treatment of acute venous thromboembolism.;Schulman;N Engl J Med,2009

2. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.;Schulman;Circulation,2014

3. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.;Büller;N Engl J Med,2013

4. Oral apixaban for the treatment of acute venous thromboembolism.;Agnelli;N Engl J Med,2013

5. Oral rivaroxaban for symptomatic venous thromboembolism.;Bauersachs;N Engl J Med,2010

Cited by 604 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A pharmacokinetic and pharmacodynamic evaluation of asundexian: a novel factor XIa inhibitor for stroke prevention;Expert Opinion on Drug Metabolism & Toxicology;2024-09-11

2. Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation;Expert Opinion on Drug Metabolism & Toxicology;2024-09-02

3. Approach to pulmonary embolism for frontline clinicians;Singapore Medical Journal;2024-09

4. Preventative and curative treatment of venous thromboembolic disease in cancer patients;La Presse Médicale;2024-09

5. Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH;Blood Reviews;2024-09